FDA approves new breakthrough therapy for cystic fibrosis - FDA Press Releases

FDA approves breakthrough therapy Trikafta for patients 12 and older with cystic fibrosis who have at least one F508del mutation in the CFTR gene, estimated to represent 90% of the cystic fibrosis population.

from FDA Press Releases RSS Feed https://ift.tt/32yxSZP
via IFTTT